INVO Bioscience, a US-based medical device company, recently announced a deal with Medesole, a leading supplier of healthcare products in India and the Middle East. The agreement allows Medesole to distribute INVO’s revolutionary fertility treatment device, INVOcell, across India. INVOcell is an innovative and cost-effective treatment for patients diagnosed with infertility, including those with Polycystic Ovarian Syndrome (PCOS). It offers an alternative to traditional IVF procedures, potentially helping couples in the UK considering fertility treatments. The company has also issued new warrants to purchase common stock.